# Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

> clinical trial · VERIFIED · 2026-06-03

Status: RECRUITING · Sponsor: Beijing Biotech · Condition: Recurrent or Metastatic Esophageal Adenocarcinoma

- Company: Beijing Biotech
- Sector: cell therapy
- Primary source: https://clinicaltrials.gov/study/NCT07622940

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.